Pi Therapeutics
Inhibitors for Cancer Treatment
Company Overview
Snapshot
Founded in March 2015 by Ori Kalid, Pi Therapeutics operated with 1–10 employees. The company raised a total of $19.7 million across two funding rounds from 11 investors. In May 2019, Pi Therapeutics announced a $19.7 million Series B financing round.
Business overview
Pi Therapeutics is a preclinical-stage pharmaceutical company focused on developing protein degradation modulators for cancer treatment. The company's lead drug modulates proteostasis-related pathways, offering a differentiated approach to preferentially target cancer cells. Targeting both hematologic and solid tumor indications, Pi Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In May 2019, Pi Therapeutics announced a $19.7 million Series B financing. This significant capital infusion underscored investor confidence in the company's preclinical data, which demonstrated a compelling safety and efficacy profile for its protein degradation inhibitors, signaling strong potential for advancing its cancer treatment pipeline.
Company Intelligence Q&A
- What is Pi Therapeutics' primary focus?
- Pi Therapeutics is a preclinical-stage pharmaceutical company dedicated to developing protein degradation modulators for the treatment of cancer.
- When was Pi Therapeutics founded?
- Pi Therapeutics was founded in March 2015.
- What was a key funding event for Pi Therapeutics?
- In May 2019, Pi Therapeutics announced a $19.7 million Series B financing round. This round included investments from Pontifax and RMGP Biopharma Investment Fund.
- What is the status of Pi Therapeutics?
- Pi Therapeutics is currently non-active and ceased to operate in April 2023.
- Which investors participated in Pi Therapeutics' January 2017 funding round?
- In January 2017, Pi Therapeutics received funding from investors including Pontifax and Johnson &.